News | July 14, 2009

ACRIN's PET Core Laboratory Provides QA Tool for Research

Deputy Co-chair and Medical Director, PET Core Laboratory, ACRIN, Barry A. Siegel, M.D.

July 14, 2009 - ACRIN has developed a qualification procedure for Positron Emission Tomography (PET) scanners at participating institutions designed to check the basic system calibrations and to verify that the clinical image quality is adequate for semiquantitative analysis of PET data, reported a paper published online in the Journal of Nuclear Medicine, Vol. 50, No. 7, on June 12, 2009. 
The American College of Radiology (ACR) Image Metrix works closely with the American College of Radiology Imaging Network (ACRIN) to conduct PET trials. The PET core laboratory of ACRIN qualifies sites to participate in multicenter research trials by reviewing the quantitative data of PET scans and qualitatively reviewing clinical PET images from each site.

Of 101 detailed scanner applications, 12 percent failed because of incorrect standardized uptake value (SUV) or normalization calibrations. Minimizing errors in SUV measurement is critical to achieving accurate quantification in clinical trials. ACRIN’s PET core laboratory shows that many sites are unable to maintain accurate SUV calibrations without additional training or supervision.

“Information obtained from PET imaging has increasingly demonstrated its promising role as a non-invasive biomarker for assessing disease status,” stated lead author, Joshua Scheuermann, MS, clinical physicist at the University of Pennsylvania. “The goal of the PET qualification program is to ensure we are obtaining reliable quantitative and qualitative data across all of the centers participating in PET clinical research.” 
  
“The emerging role of PET imaging endpoints as in vivo biomarkers requires imaging studies to produce reliable quantitative, semi-quantitative and qualitative results that can be used to assess disease status. Ensuring such consistency in multi-center clinical trials that involve imaging is problematic. The problem stems from the fact that the data acquisition and reconstruction are performed in many different settings and often with different types of instrumentation.  As described in our most recent peer reviewed publication, ACRIN has managed to develop a robust system to streamline data collection, data management and processing.  Such system is paving the way for a better integration of molecular imaging in drug discovery processes,” stated Deputy Co-chair and Medical Director, PET Core Laboratory, ACRIN, Barry A. Siegel, M.D. 
 
“The results from this highlight the importance of a central review of a site’s data and images before data from a PET scanner can be used,” stated ACR Image Metrix General Manager, Michael Morales. “The PET core laboratory is a key component of our research center providing accurate, reliable research results.”

For more information: www.acr-imagemetrix.net and www.acrin.org

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Overlay Init